Hybrigenics Announces its First Victory Against an American Patent

Hybrigenics announces its first victory against an American patent granted to Forma Therapeutics concerning inhibitors of UbiquitinSpecific Protease No. 7 (USP7), by a decision of the US Patent and Trademark Office.

This decision invalidates 16 of the 17 claims of patent US9,840,491 which relates to specific inhibitors of USP7 belonging to the same chemical class as those of patent US9,546,150 of Hybrigenics filed four years before Forma Therapeutics.

The company explains that USP7 inhibitors prevent the recycling of many onco-proteins by USP7 and promote their degradation; in doing so, they have the potential to slow the progression of certain cancers.

Reviewer overview

Hybrigenics Announces its First Victory Against an American Patent - /10

Summary

Hybrigenics announces its first victory against an American patent granted to Forma Therapeutics concerning inhibitors...

0 Bad!